News_克睿基因生物科技有限公司

En Ch

Home

About Us

Introduction

History

Team

Scientific Advisory Board

Science

Technology Platform

Pipeline

Collaborations

News

News

Join Us

Culture

Careers opportunities

Contact information

CureGenetics Announces Promising Phase I clinical ...

CureGenetics Announces Promising Phase I clinical ...

CGC729 continues to demonstrate a favorable safety profile and promising efficacy signals in heavily pretreated ccRCC patients.

More

Cure Genetics announced the interim data of CAR-NK...

Cure Genetics announced the interim data of CAR-NK...

This marked the first human trial using CAR-NKT therapy for RCC, demonstrating its good safety profile and anti-tumor activity.

More

Cure Genetics Awarded Third Place in the 2024 Biom...

Cure Genetics Awarded Third Place in the 2024 Biom...

Cure Genetics distinguished itself from nearly a hundred international projects and was awarded third place in the 2024 Biomedical Pitch Competition

More

Cure Genetics to Unveil Groundbreaking Achievemen...

Cure Genetics to Unveil Groundbreaking Achievemen...

Cure Genetics will present for the first time the latest advancements of the CAR-NKT product CGC729 for RCC treatment through an oral presentation at the 2024 ASGCT Annual Meeting, and will also showcase four research findings related to the development of AAV serotypes.

More

A novel PD-1-IL-2v bispecific molecule for cancer ...

A novel PD-1-IL-2v bispecific molecule for cancer ...

The journal Frontiers in Immunology recently reported on Cure Genetics' developed CGC-602 bispecific antibody molecule, which targets both PD-1 and IL-2. The IL-2v component is a variant derived from wild-type IL-2.

More